Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer
Endometrial cancer (EC) is the most common gynecologic malignancy, with worldwide increasing incidence and disease-associated mortality. Although most patients with EC are diagnosed with early-stage disease, systemic treatment options for patients with advanced or recurrent EC have historically been limited. EC-focused clinical trials and the ensuing therapeutic landscape have expanded since The Cancer Genome Atlas (TCGA) identified 4 distinct EC subgroups associated with differential survival. This endeavor revolutionized our understanding of the genomic characterization of EC as well as molecular drivers of this heterogeneous malignancy, leading to precision oncology approaches to therapeutics and advancement in treatment options. This review describes the current status of and recent advancements in therapeutic options for patients with advanced and recurrent EC. The NCCN Guidelines for Uterine Neoplasms provide detailed recommendations regarding the diagnosis, workup, and management of EC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Journal of the National Comprehensive Cancer Network : JNCCN - 21(2023), 2 vom: 17. Feb., Seite 217-226 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gordhandas, Sushmita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advanced endometrial cancer |
|---|
| Anmerkungen: |
Date Completed 17.02.2023 Date Revised 02.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.6004/jnccn.2022.7254 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352982950 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352982950 | ||
| 003 | DE-627 | ||
| 005 | 20240202231932.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.6004/jnccn.2022.7254 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM352982950 | ||
| 035 | |a (NLM)36791759 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gordhandas, Sushmita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.02.2023 | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Endometrial cancer (EC) is the most common gynecologic malignancy, with worldwide increasing incidence and disease-associated mortality. Although most patients with EC are diagnosed with early-stage disease, systemic treatment options for patients with advanced or recurrent EC have historically been limited. EC-focused clinical trials and the ensuing therapeutic landscape have expanded since The Cancer Genome Atlas (TCGA) identified 4 distinct EC subgroups associated with differential survival. This endeavor revolutionized our understanding of the genomic characterization of EC as well as molecular drivers of this heterogeneous malignancy, leading to precision oncology approaches to therapeutics and advancement in treatment options. This review describes the current status of and recent advancements in therapeutic options for patients with advanced and recurrent EC. The NCCN Guidelines for Uterine Neoplasms provide detailed recommendations regarding the diagnosis, workup, and management of EC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a advanced endometrial cancer | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a recurrent endometrial cancer | |
| 650 | 4 | |a systemic therapy | |
| 650 | 4 | |a targeted therapy | |
| 700 | 1 | |a Zammarrelli, William A |e verfasserin |4 aut | |
| 700 | 1 | |a Rios-Doria, Eric V |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Angela K |e verfasserin |4 aut | |
| 700 | 1 | |a Makker, Vicky |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the National Comprehensive Cancer Network : JNCCN |d 2003 |g 21(2023), 2 vom: 17. Feb., Seite 217-226 |w (DE-627)NLM156397676 |x 1540-1413 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:2 |g day:17 |g month:02 |g pages:217-226 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.6004/jnccn.2022.7254 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 2 |b 17 |c 02 |h 217-226 | ||